Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
141
Completed, industry sponsors, Dermatology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed141
141 trials
Showing 1 to 25, recently updated first.
- A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.Pivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT07795567 · 865 participants · Start Dec 9, 2025 · Primary completion Jun 24, 2026
Drug: Ivermectin Cream 1%; Soolantra™ Cream 1% and 2 more · For: Rosacea
Sites: Hawthorne, New York
SATO Pharmaceutical Co., Ltd.Industry
NCT05110638 · 19 participants · Start Sep 22, 2021 · Primary completion May 30, 2022
Drug: SKX-16 (Luliconazole 10% Solution) · For: Onychomycosis of Toenail
Sites: College Station, Texas
Azitra Inc.Industry
NCT06137157 · 6 participants · Start Jun 16, 2024 · Primary completion Jul 7, 2026
Drug: ATR12-351 · For: Netherton Syndrome
Sites: Palo Alto, California; New Haven, Connecticut
- A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT07469228 · 1,043 participants · Start Aug 4, 2025 · Primary completion Dec 15, 2025
Drug: Tretinoin Gel Microsphere, 0.04%; RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04% and 1 more · For: Acne Vulgaris
Sites: Hawthorne, New York
Genzada Pharmaceuticals USA, Inc.Industry
NCT06888362 · 41 participants · Start Aug 19, 2024 · Primary completion Mar 31, 2025
Drug: GZ21T · For: Actinic Keratosis
Sites: Uppsala, Sweden
PfizerPfizer (PFE)
NCT06671834 · 52 participants · Start Nov 22, 2024 · Primary completion Dec 4, 2025
Drug: PF-07905428; Placebo · For: Acne Vulgaris
Sites: Montreal, Canada
Sixera PharmaIndustry
NCT05211830 · 9 participants · Start Dec 7, 2021 · Primary completion Jun 10, 2025
Drug: SXR1096 cream; Placebo cream · For: Netherton Syndrome
Sites: Innsbruck, Austria; Paris, France; Freiburg im Breisgau, Germany · 5 sites in all
- Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT04321070 · 550 participants · Start Sep 9, 2019 · Primary completion Dec 14, 2019
Drug: Clindamycin Phosphate; Clindamycin Phosphate RLD and 1 more · For: Acne Vulgaris
Sites: Charlotte, North Carolina
- Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT01820260 · 395 participants · Start Apr 2013 · Primary completion Aug 2014
Drug: Ingenol mebutate gel; placebo · For: Actinic Keratosis
Sites: Carmel, Indiana
- PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal MicroscopyCompleted
LEO PharmaIndustry
NCT01449513 · 24 participants · Start Sep 2011 · Primary completion May 2012
Drug: Ingenol mebutate; Placebo Gel · For: Actinic Keratosis
Sites: Berlin, Germany
- Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT02100813 · 220 participants · Start May 2014 · Primary completion Mar 2015
Drug: LEO 43204; Placebo · For: Actinic Keratosis
Sites: Snellville, Georgia
- A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT01922050 · 320 participants · Start Oct 2013 · Primary completion Nov 2014
Drug: LEO 43204 Formulation 1; LEO 43204 Formulation 2 and 6 more · For: Actinic Keratosis
Sites: Phoenix, Arizona; Lomita, California; San Diego, California · 25 sites in all
- Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic KeratosisPivotal-lookingCompleted
LEO PharmaIndustry
NCT02120456 · 224 participants · Start May 2014 · Primary completion May 2015
Drug: LEO 43204; Placebo · For: Actinic Keratosis
Sites: Phoenix, Arizona; Lomita, California; San Diego, California · 21 sites in all
LEO PharmaIndustry
NCT01892137 · 137 participants · Start Jul 2013 · Primary completion Mar 2014
Drug: Ingenol mebutate gel 0.05% · For: Actinic Keratosis
Sites: Kogarah, Australia; North Sydney, Australia; Benowa, Australia · 10 sites in all
LEO PharmaIndustry
NCT02124239 · 79 participants · Start Apr 2014 · Primary completion Nov 2014
Drug: Ingenol mebutate · For: Actinic Keratosis
Sites: Albuquerque, New Mexico
LEO PharmaIndustry
NCT02600598 · 24 participants · Start Jul 2016 · Primary completion Dec 27, 2016
Drug: LEO 43204 Gel, 0.037%; LEO 43204 Gel, 0.037% · For: Actinic Keratosis
Sites: Quincy, Massachusetts; Smithtown, New York
- Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use ConditionsCompleted
LEO PharmaIndustry
NCT02424305 · 60 participants · Start May 2015 · Primary completion Jul 2015
Drug: LEO 43204 gel 0.018%; LEO 43204 gel 0.1% and 1 more · For: Actinic Keratosis
Sites: Pflugerville, Texas
LEO PharmaIndustry
NCT01703078 · 41 participants · Start Nov 2012 · Primary completion Mar 2013
Drug: Ingenol once daily for two consecutive days · For: Actinic Keratosis
Sites: Woolloongabba, Australia
- A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 GelPivotal-lookingCompleted
LEO PharmaIndustry
NCT02650505 · 233 participants · Start Feb 2016 · Primary completion Jun 2016
Drug: LEO 43204; LEO 43204 Vehicle · For: Actinic Keratosis
Sites: Fair Lawn, New Jersey
LEO PharmaIndustry
NCT01803477 · 37 participants · Start Feb 2013 · Primary completion Oct 2013
Drug: once daily for two consecutive days (Picato) · For: Actinic Keratosis
Sites: Woolloongabba, Australia · 2 sites in all
LEO PharmaIndustry
NCT01387711 · 27 participants · Start Aug 2011 · Primary completion Jun 2012
Drug: PEP005 (Ingenol mebutat Gel, 0.05 %) · For: Actinic Keratosis
Sites: Göttingen, Germany
- Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult SubjectsCompleted
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
NCT06454708 · 12 participants · Start Aug 1, 2024 · Primary completion Aug 12, 2024
Drug: Clascoterone Cream 1% · For: Acne Vulgaris
Sites: London, China
- A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT06733402 · 1,000 participants · Start Jun 20, 2024 · Primary completion Jun 20, 2024
Drug: Trifarotene Cream 0.005%; AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG and 2 more · For: Acne Vulgaris
Sites: Hawthorne, New York
- A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.Pivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT06673641 · 382 participants · Start May 13, 2024 · Primary completion Sep 3, 2024
Drug: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%; CABTREO Topical Gel and 1 more · For: Acne Vulgaris
Sites: Hawthorne, New York
- To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy SubjectsCompleted
Suzhou Kintor Pharmaceutical Inc,Industry
NCT06468579 · 92 participants · Start Jul 25, 2021 · Primary completion Aug 15, 2022
Drug: GT20029; GT20029 matching placebo · For: Acne; Alopecia
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.